{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:44:48Z","timestamp":1786121088467,"version":"build-2736575974"},"reference-count":84,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018996","name":"Hellenic Academic Libraries Link","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.autrev.2026.104136","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:26:13Z","timestamp":1783351573000},"page":"104136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer-associated dermatomyositis: A scoping review of the literature"],"prefix":"10.1016","volume":"25","author":[{"given":"Melina","family":"Yerolatsite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Kekkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanteznta","family":"Torounidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafsika","family":"Gerolymatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Zarkavelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi V.","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2026.104136_bb0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.clindermatol.2006.07.001","article-title":"Dermatomyositis","volume":"24","author":"Callen","year":"2006","journal-title":"Clin Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104136_bb0010","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s00105-015-3659-0","article-title":"Dermatomyositis-update","volume":"66","author":"Volc-Platzer","year":"2015","journal-title":"Hautarzt"},{"issue":"8","key":"10.1016\/j.autrev.2026.104136_bb0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104136_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1684\/ejd.2020.3761","article-title":"The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants","volume":"30","author":"Didona","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104136_bb0030","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/art.24547","article-title":"Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis","volume":"60","author":"Gunawardena","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104136_bb0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2026.104136_bb0040","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","article-title":"Anti-MDA5 antibody is associated with a\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis","volume":"32","author":"Chen","year":"2012","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2026.104136_bb0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104136_bb0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104136_bb0055","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2026.104136_bb0060","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0065","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104136_bb0070","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0075","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.autrev.2026.104136_bb0080","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104136_bb0085","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/archotol.1995.01890110072013","article-title":"Nasopharyngeal carcinoma with dermatomyositis: analysis of 12 cases","volume":"121","author":"Peng","year":"1995","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"5","key":"10.1016\/j.autrev.2026.104136_bb0090","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0190-9622(97)70109-9","article-title":"Ovarian malignancy in patients with dermatomyositis and polymyositis: a retrospective analysis of fourteen cases","volume":"37","author":"Davis","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104136_bb0095","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1046\/j.1365-4362.1997.00190.x","article-title":"Malignancy in adult dermatomyositis","volume":"36","author":"Leow","year":"1997","journal-title":"Int J Dermatol"},{"issue":"9250","key":"10.1016\/j.autrev.2026.104136_bb0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2026.104136_bb0105","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1365-2133.2001.04140.x","article-title":"Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study","volume":"144","author":"Chen","year":"2001","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104136_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.138.7.885","article-title":"Routine vs extensive malignancy search for adult dermatomyositis and polymyositis","volume":"138","author":"Sparsa","year":"2002","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104136_bb0115","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1046\/j.1365-4362.2002.01648.x","article-title":"Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study","volume":"41","author":"Wakata","year":"2002","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104136_bb0120","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1067\/mjd.2003.208","article-title":"Dermatomyositis and malignancy in Tunisia: a multicenter national retrospective study of 20 cases","volume":"48","author":"Mebaz\u00e2a","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104136_bb0125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1361.047","article-title":"Cancer-associated myositis: clinical features and prognostic signs","volume":"1051","author":"Ponyi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104136_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104136_bb0135","first-page":"438","article-title":"Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study","volume":"35","author":"Andr\u00e1s","year":"2008","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104136_bb0140","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2133.2009.09274.x","article-title":"Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study","volume":"161","author":"Huang","year":"2009","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104136_bb0145","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3899\/jrheum.090549","article-title":"Malignancy is associated with dermatomyositis but not polymyositis in northern New England, USA","volume":"36","author":"Antiochos","year":"2009","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0150","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/ar2987","article-title":"Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan","volume":"12","author":"Chen","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3109\/s10165-010-0362-y","article-title":"Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis","volume":"21","author":"Azuma","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104136_bb0160","doi-asserted-by":"crossref","first-page":"843","DOI":"10.47102\/annals-acadmedsg.V39N11p843","article-title":"An 11-year review of dermatomyositis in Asian patients","volume":"39","author":"Liu","year":"2010","journal-title":"Ann Acad Med Singap"},{"issue":"11","key":"10.1016\/j.autrev.2026.104136_bb0165","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3899\/jrheum.110320","article-title":"Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis","volume":"38","author":"So","year":"2011","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104136_bb0170","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1346-8138.2011.01262.x","article-title":"Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients","volume":"38","author":"Ikeda","year":"2011","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104136_bb0175","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2133.2011.10595.x","article-title":"Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study","volume":"165","author":"Kuo","year":"2011","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104136_bb0180","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.autrev.2011.10.024","article-title":"Hematological malignancy associated with polymyositis and dermatomyositis","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2026.104136_bb0185","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-4632.2011.05449.x","article-title":"A comparative study of clinical characteristics, work-up, treatment, and association to malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore","volume":"52","author":"Yosipovitch","year":"2013","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0190","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4103\/0028-3886.111121","article-title":"Incidence of malignancies in biopsy-proven inflammatory myopathy","volume":"61","author":"Kannan","year":"2013","journal-title":"Neurol India"},{"issue":"11","key":"10.1016\/j.autrev.2026.104136_bb0195","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104136_bb0200","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/his.14727","article-title":"Histopathological risk factors for malignancy in dermatomyositis","volume":"81","author":"Pruessmann","year":"2022","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.autrev.2026.104136_bb0205","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/art.42311","article-title":"Subsets of idiopathic inflammatory myositis enriched for contemporaneous cancer relative to the general population","volume":"75","author":"Mecoli","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104136_bb0210","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00296-013-2910-1","article-title":"Cancer-associated myositis: a 35-year retrospective study of a monocentric cohort","volume":"34","author":"Neri","year":"2014","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.autrev.2026.104136_bb0215","first-page":"731","article-title":"Low prevalence of malignancy in patients with idiopathic inflammatory myopathies in Jordan","volume":"33","author":"Mustafa","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"Pt 8","key":"10.1016\/j.autrev.2026.104136_bb0220","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.autrev.2026.104136_bb0225","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaad.2018.01.002","article-title":"Malignancy-associated dermatomyositis: retrospective case-control study from a single tertiary care center","volume":"79","author":"Kooistra","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104136_bb0230","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.170544","article-title":"Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis","volume":"45","author":"Chen","year":"2018","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104136_bb0235","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/1756-185X.13352","article-title":"Long-term follow-up of 76 Iranian patients with idiopathic inflammatory myopathies","volume":"21","author":"Hajialilo","year":"2018","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104136_bb0240","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jaad.2018.11.023","article-title":"Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis","volume":"80","author":"Hoesly","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104136_bb0245","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104136_bb0250","first-page":"67","article-title":"Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study","volume":"38","author":"Dani","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104136_bb0255","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2020.02.061","article-title":"Malignancy in dermatomyositis: a retrospective study of 201 patients seen at the University of Pennsylvania","volume":"83","author":"Bowerman","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104136_bb0260","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/1346-8138.15526","article-title":"Clinical features of anti-transcription intermediary factor 1\u03b3 (TIF1\u03b3)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1\u03b3 expression in tumors in the pathogenesis of cancer-associated dermatomyositis","volume":"47","author":"Motegi","year":"2020","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104136_bb0265","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00403-020-02127-5","article-title":"Characteristics of hospitalized dermatomyositis patients with underlying malignancy: a nationally representative retrospective cohort study","volume":"313","author":"Tripathi","year":"2021","journal-title":"Arch Dermatol Res"},{"issue":"34","key":"10.1016\/j.autrev.2026.104136_bb0270","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021899","article-title":"Clinical characteristics and prognostic analysis of Chinese dermatomyositis patients with malignancies","volume":"99","author":"Shao","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104136_bb0275","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.semarthrit.2020.12.009","article-title":"Overall and site-specific cancer before and after diagnosis of idiopathic inflammatory myopathies: a nationwide study 2002-2016","volume":"51","author":"Dani","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2026.104136_bb0280","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1093\/rheumatology\/keab260","article-title":"TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1\u03b3 positive cancer-associated dermatomyositis","volume":"60","author":"Cordel","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104136_bb0285","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.12957","article-title":"NanoString technology distinguishes anti-TIF-1\u03b3+ from anti-Mi-2+ dermatomyositis patients","volume":"31","author":"Preusse","year":"2021","journal-title":"Brain Pathol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104136_bb0290","first-page":"1601","article-title":"Characteristics of dermatomyositis patients with and without associated malignancy","volume":"19","author":"Lauinger","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0295","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-021-08920-y","article-title":"An Italian multicenter study on anti-NXP2 antibodies: clinical and serological associations","volume":"63","author":"Fredi","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0300","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/ard-2022-222441","article-title":"Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1\u03b3 autoantibodies","volume":"82","author":"Hosono","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104136_bb0305","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10067-022-06425-3","article-title":"Circulating VEGF-A, TNF-\u03b1, CCL2, IL-6, and IFN-\u03b3 as biomarkers of cancer in cancer-associated anti-TIF1-\u03b3 antibody-positive dermatomyositis","volume":"42","author":"Li","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104136_bb0310","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/art.42474","article-title":"Association of Anti-CCAR1 autoantibodies with decreased cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1\u03b3-positive dermatomyositis","volume":"75","author":"Fiorentino","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104136_bb0315","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1093\/rheumatology\/kead154","article-title":"Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature","volume":"62","author":"Demortier","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104136_bb0320","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/rheumatology\/kead222","article-title":"Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis","volume":"63","author":"Shih","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104136_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152283","article-title":"Obesity is an independent risk factor for cancer development following diagnosis of dermatomyositis","volume":"64","author":"Allenzara","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2026.104136_bb0330","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.reuma.2024.04.002","article-title":"Exploring the link between inflammatory myopathies and cancer: a comprehensive retrospective analysis in a Colombian cohort","volume":"20","author":"Bola\u00f1os","year":"2024","journal-title":"Reumatol Clin"},{"issue":"12","key":"10.1016\/j.autrev.2026.104136_bb0335","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/1346-8138.17426","article-title":"Clinical and laboratory features between anti-TIF1\u03b3 dermatomyositis with and without malignancy: 37 case series and a review","volume":"51","author":"Tang","year":"2024","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104136_bb0340","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdermsci.2021.10.003","article-title":"Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1\u03b3 antibodies","volume":"104","author":"Ly","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104136_bb0345","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12885-016-2715-1","article-title":"Dermatomyositis with anti-TIF-1\u03b3 antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report","volume":"16","author":"Kube\u010dek","year":"2016","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.autrev.2026.104136_bb0350","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/1756-185X.13449","article-title":"A case of cancer-associated myositis with anti-Mi-2 antibody: false-positive anti-transcriptional intermediary factor 1-\u03b3 antibody by commercial enzyme-linked immunosorbent assay","volume":"22","author":"Nawata","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104136_bb0355","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/1346-8138.13579","article-title":"Case of anti-transcriptional intermediary factor-1-positive dermatomyositis associated with breast cancer developing over 10 years","volume":"44","author":"Matsushita","year":"2017","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0360","first-page":"115","article-title":"Dermatomyositis associated with thymoma: a case report and literature review","volume":"174","author":"Y\u0131ld\u0131r\u0131m","year":"2023","journal-title":"Clin Ter"},{"issue":"12","key":"10.1016\/j.autrev.2026.104136_bb0365","doi-asserted-by":"crossref","first-page":"e1403","DOI":"10.1111\/jdv.19339","article-title":"Rapidly progressive erosions and ulcerations in a patient with cancer-associated anti-TIF-1\u03b3\/\u03b1 and anti-U1 RNP-positive dermatomyositis: a case report","volume":"37","author":"Rosseels","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 Pt 1","key":"10.1016\/j.autrev.2026.104136_bb0370","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0190-9622(97)70109-9","article-title":"Ovarian malignancy in patients with dermatomyositis and polymyositis: a retrospective analysis of fourteen cases","volume":"37","author":"Davis","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104136_bb0375","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4254\/wjh.v5.i4.230","article-title":"Dermatomyositis associated with gallbladder carcinoma: a case report","volume":"5","author":"Ni","year":"2013","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104136_bb0380","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40674-022-00197-2","article-title":"Management of cancer-associated myositis","volume":"8","author":"A","year":"2022","journal-title":"Curr Treat Options Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0385","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/art.42345","article-title":"Genetic influences in <scp>cancer-associated<\/scp> myositis","volume":"75","author":"Patasova","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0390","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2026.104136_bb0395","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/ijc.24484","article-title":"HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological stage C colorectal cancers","volume":"125","author":"Walsh","year":"2009","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2026.104136_bb0400","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2005.11.011","article-title":"CD8+HLA-DR+ T lymphocytes are increased in common variable immunodeficiency patients with impaired memory B-cell differentiation","volume":"119","author":"Viallard","year":"2006","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104136_bb0405","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2249.2001.01623.x","article-title":"HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus","volume":"125","author":"Viallard","year":"2001","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104136_bb0410","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5114\/reum.2015.51510","article-title":"Polymyositis and dermatomyositis as a risk of developing cancer","volume":"53","author":"Jakubaszek","year":"2015","journal-title":"Reumatologia"},{"issue":"6","key":"10.1016\/j.autrev.2026.104136_bb0415","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/ced.13180","article-title":"Expression of the autoantigen TRIM33\/TIF1\u03b3 in skin and muscle of patients with dermatomyositis is upregulated, together with markers of cellular stress","volume":"42","author":"Scholtissek","year":"2017","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104136_bb0420","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nrc3139","article-title":"TRIM proteins and cancer","volume":"11","author":"Hatakeyama","year":"2011","journal-title":"Nat Rev Cancer"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T02:59:35Z","timestamp":1786071575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1568997226001503"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104136","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-associated dermatomyositis: A scoping review of the literature","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104136"}}